Considering that 2-APB is not a selective STOC blocker, new drugs with a selective effects on ORAI1/STIM1 interaction are needed to evaluate the role of the STOC in OSA patients with pulmonary hypertension (Reyes et al., 2018; Waldron et al., 2019). Here, ORAI1 is linked to pulmonary hypertension.